These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25673034)

  • 1. Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
    Uwagawa T; Yanaga K
    Surg Today; 2015 Dec; 45(12):1481-8. PubMed ID: 25673034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
    Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
    Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
    Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
    Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
    Sun W; Haller D
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):16-9. PubMed ID: 14569842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
    Müerköster S; Arlt A; Witt M; Gehrz A; Haye S; March C; Grohmann F; Wegehenkel K; Kalthoff H; Fölsch UR; Schäfer H
    Int J Cancer; 2003 Apr; 104(4):469-76. PubMed ID: 12584745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.
    Ahn DW; Seo JK; Lee SH; Hwang JH; Lee JK; Ryu JK; Kim YT; Yoon YB
    Pancreas; 2012 Oct; 41(7):1048-57. PubMed ID: 22513291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
    Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
    Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
    Mamaghani S; Patel S; Hedley DW
    BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
    Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP
    Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.
    Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
    J Am Coll Surg; 2004 Apr; 198(4):591-9. PubMed ID: 15051014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
    Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
    J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
    Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.